All In Biotech

Drug Trial Radar · NCT06742853

A Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of AZD0780 With Ezetimibe Combinations in Healthy Adults With Elevated LDL-C.

A Phase 1, Randomized, Single-blind, Placebo-controlled Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of AZD0780 in Combination With Ezetimibe, Ezetimibe/Rosuvastatin, or Ezetimibe/Bempedoic Acid in Healthy Male and Female Participants 18 to 75 Years of Age With Elevated LDL-C.

Last checked: Nov 19, 2026Latest source record: Nov 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

81

Actual

Start

Dec 20, 2024

Primary completion

Oct 29, 2025

Study completion Oct 29, 2025

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Dec 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The main aim of this study is to assess the effects of AZD0780 when added on top of ezetimibe or ezetimibe and rosuvastatin or ezetimibe and bempedoic acid.

Conditions

  • Dyslipidemia

Interventions

  • AZD0780Drug

    AZD0780 tablet will be administered orally.

  • EzetimibeDrug

    Ezetimibe tablet will be administered orally.

  • RosuvastatinDrug

    Rosuvastatin tablet will be administered orally.

  • Bempedoic AcidDrug

    Bempedoic Acid tablet will be administered orally.

  • PlaceboDrug

    Placebo will be administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in direct Low-density Lipsprotein Cholesterol (LDL-C)Time frame: Week 4
  2. Number of participants with adverse eventsTime frame: From screening (Day -56 to -29) to 14 Weeks

Locations

3 sites in 2 countries. Site status is shown where the registry gives one.

  • Research Site

    Glendale, California

  • Research Site

    Brooklyn, Maryland

  • Research Site

    Harrow, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.